

Ref: FOI/GS/ID 7674

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

17 October 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Cervical cancer and Endometrial cancer.

You asked:

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for the following conditions?

- a. Cervical cancer*
- b. Endometrial cancer*

In case you do not provide SACT treatments for either of the above conditions, which other trust do you refer patients to for these treatments?

Q2. How many patients were treated for cervical cancer in the past 6 months with the following treatments:

- a. Paclitaxel in combination with Platinum and/or Bevacizumab*
- b. Pembrolizumab in combination with Platinum and/or Bevacizumab*
- c. Platinum standalone or in combination with Bevacizumab*
- d. Topotecan in combination with Platinum and/or Bevacizumab*
- e. Any other SACT*

Q3. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:

- a. Dostarlimab*
- b. Hormone therapy (Progesterone or Letrozole)*
- c. Pembrolizumab in combination with Lenvatinib*
- d. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)*
- e. Any other SACT*

Q4. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:

- a. Hormone therapy (Progesterone or Letrozole)*

b. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)

c. Any other SACT

Q5. Does your trust participate in any clinical trials for the treatment of cervical cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Q6. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Trust response:

Q1.

a. Yes

b. Yes

In case you do not provide SACT treatments for either of the above conditions, which other trust do you refer patients to for these treatments?

Q2.

a. 2

b. 0

c. 8

d. 0

e. 0

3.

a. 1

b. 1

c. 0

d. 31

e. 4

Q4.

a. 1

b. 7

c. 0

Q5. COMICE - A randomized double blind placebo controlled Phase II clinical trial of Cediranib and Olaparib maintenance in advanced recurrent Cervical Cancer. (IRAS 209375)

1 patient recruited

Q6. None currently.